"On December 16, 2014, the U. S. Food and Drug Administration approved lanreotide (Somatuline Depot Injection, Ipsen Pharma) for the treatment of patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroe"...
No specific information is available on the treatment of overdose with pomalidomide, and it is unknown whether pomalidomide or its metabolites are dialyzable.
POMALYST can cause fetal harm when administered to a pregnant female [see WARNINGS AND PRECAUTIONS and Use in Specific Populations]. POMALYST is contraindicated in females who are pregnant. Pomalidomide is a thalidomide analogue and is teratogenic in both rats and rabbits when administered during the period of organogenesis. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 5/12/2015
Additional Pomalyst Information
Report Problems to the Food and Drug Administration
Get the latest treatment options.